Key statistics
On Wednesday, Cyclacel Pharmaceuticals Inc (CYCCP:NAQ) closed at 7.00, 33.33% above the 52 week low of 5.25 set on Nov 08, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.36 |
---|---|
High | 7.36 |
Low | 7.00 |
Bid | 0.0001 |
Offer | -- |
Previous close | 7.00 |
Average volume | 609.50 |
---|---|
Shares outstanding | 1.97m |
Free float | 1.87m |
P/E (TTM) | -- |
Market cap | 1.93m USD |
EPS (TTM) | -16.14 USD |
Annual div (ADY) | -- |
---|---|
Annual div yield (ADY) | -- |
Div ex-date | Jan 19 2024 |
Div pay-date | Feb 01 2024 |
Data delayed at least 15 minutes, as of Sep 18 2024 20:59 BST.
More ▼
Announcements
- Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference
- Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter
- Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
- Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results
- Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions
- Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting
- Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer
- Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
- Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results
- Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules
More ▼